CA2378182C - Compositions and methods for the treatment of tumors - Google Patents

Compositions and methods for the treatment of tumors Download PDF

Info

Publication number
CA2378182C
CA2378182C CA2378182A CA2378182A CA2378182C CA 2378182 C CA2378182 C CA 2378182C CA 2378182 A CA2378182 A CA 2378182A CA 2378182 A CA2378182 A CA 2378182A CA 2378182 C CA2378182 C CA 2378182C
Authority
CA
Canada
Prior art keywords
adam8
antibody
expression
polypeptide
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2378182A
Other languages
English (en)
French (fr)
Other versions
CA2378182A1 (en
Inventor
Sarah C. Bodary
Karen L. Fisher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CA2378182A1 publication Critical patent/CA2378182A1/en
Application granted granted Critical
Publication of CA2378182C publication Critical patent/CA2378182C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2378182A 1999-07-28 2000-07-27 Compositions and methods for the treatment of tumors Expired - Lifetime CA2378182C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14621799P 1999-07-28 1999-07-28
US60/146,217 1999-07-28
PCT/US2000/020731 WO2001009189A2 (en) 1999-07-28 2000-07-27 Compositions and methods for the treatment of tumors

Publications (2)

Publication Number Publication Date
CA2378182A1 CA2378182A1 (en) 2001-02-08
CA2378182C true CA2378182C (en) 2014-09-23

Family

ID=22516336

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2378182A Expired - Lifetime CA2378182C (en) 1999-07-28 2000-07-27 Compositions and methods for the treatment of tumors

Country Status (9)

Country Link
US (2) US7226596B2 (enExample)
EP (1) EP1204682B1 (enExample)
JP (3) JP2003508028A (enExample)
AT (1) ATE488529T1 (enExample)
AU (1) AU776600B2 (enExample)
CA (1) CA2378182C (enExample)
DE (1) DE60045247D1 (enExample)
ES (1) ES2355055T3 (enExample)
WO (1) WO2001009189A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2378182C (en) * 1999-07-28 2014-09-23 Genentech, Inc. Compositions and methods for the treatment of tumors
US7157567B2 (en) 2002-02-20 2007-01-02 Astellas Pharma, Inc. Polypeptide
CN101586155A (zh) * 2002-09-30 2009-11-25 肿瘤疗法科学股份有限公司 非小细胞肺癌的诊断方法
US20080014594A1 (en) * 2003-01-31 2008-01-17 Kevin Hestir Lung-Expressed Polypeptides
EP1730533A1 (en) * 2004-03-24 2006-12-13 Oncotherapy Science, Inc. Adam8 as tumor marker and therapeutic target for non-small cell lung cancer
ES2318575T3 (es) * 2004-11-10 2009-05-01 Novartis Vaccines And Diagnostics, Inc. Interferon beta desamidado.
FR2879462B1 (fr) * 2004-12-21 2008-12-26 Sod Conseils Rech Applic Utilisation de toxine botulique pour une insensibilisation locale prolongee
KR20070100307A (ko) 2004-12-22 2007-10-10 제넨테크, 인크. 가용성 다중 막관통 단백질의 생산 방법
US20060242012A1 (en) * 2005-04-22 2006-10-26 Sumit Agarwal Determining or scoring properties to solicit to join ad network using advertiser or aggregated advertiser interest
AU2007336243B2 (en) 2006-12-19 2012-07-26 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
GB2453589A (en) 2007-10-12 2009-04-15 King S College London Protease inhibition
MX2010005811A (es) * 2007-11-27 2010-06-09 Veridex Llc Enumeracion automatica y caracterizacion de las celulas del melanoma circulantes en la sangre.
WO2010081173A2 (en) * 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
WO2014186364A2 (en) * 2013-05-13 2014-11-20 Tufts University Methods and compositions for prognosis, diagnosis and treatment of adam8-expressing cancer
TW201613622A (en) * 2014-10-14 2016-04-16 Bionet Corp Composition for skincare and pharmaceutical composition and preparation method thereof
TW201613621A (en) * 2014-10-14 2016-04-16 Bionet Corp Composition for promoting growth of dermal papilla cells, pharmaceutical composition, and preparation method thereof
JP2018130113A (ja) * 2017-02-15 2018-08-23 国立大学法人 東京大学 慢性骨髄性白血病（ｃｍｌ）の検査方法及び検査用キット、チロシンキナーゼ阻害剤（ｔｋｉ）耐性ｃｍｌの単離方法、並びにｃｍｌにおけるｔｋｉ耐性の低減剤及びそのスクリーニング方法
AU2020283906A1 (en) * 2019-05-31 2022-01-20 Trustees Of Tufts College Anti-ADAM8 antibodies and uses of the same

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04187084A (ja) * 1990-11-22 1992-07-03 Otsuka Pharmaceut Co Ltd 単球表面に発現する抗原及び該抗原に対するモノクローナル抗体
DK0822186T3 (da) * 1994-01-20 2000-06-26 British Biotech Pharm L-tert-leucin-2-pyridylamid
GB9608130D0 (en) 1996-04-19 1996-06-26 Univ Sheffield Adam proteins and uses thereof
ATE244579T1 (de) * 1997-01-22 2003-07-15 Univ Texas Verfahren und zusammensetzungen des gewebefaktors zur koagulation und behandlung von tumoren
GB9705521D0 (en) * 1997-03-18 1997-05-07 Univ Sheffield The use of mononuclear phagocytes in the vivo imaging of hypoxic/ischaemic tissue
US5922566A (en) * 1997-05-13 1999-07-13 Incyte Pharmaceuticals, Inc. Tumor-associated antigen
GB2339200B (en) * 1998-06-06 2001-09-12 Genostic Pharma Ltd Genostics
WO2000040749A2 (en) * 1999-01-06 2000-07-13 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
US20010034023A1 (en) * 1999-04-26 2001-10-25 Stanton Vincent P. Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing
CA2378182C (en) * 1999-07-28 2014-09-23 Genentech, Inc. Compositions and methods for the treatment of tumors
EP1259595B1 (en) * 2000-02-25 2007-04-04 Immunex Corporation Integrin antagonists
ES2264440T3 (es) * 2000-03-24 2007-01-01 Micromet Ag Amplificacion de mrna.
US6458552B1 (en) * 2000-06-06 2002-10-01 Ortho-Mcneil Pharmaceutical, Inc. Metalloprotease peptide substrates and methods
AU2002213005A1 (en) * 2000-10-02 2002-04-15 Board Of Regents, The University Of Texas System Method of detection and interpretation of mutations through expression or function tests of haploid genes
AU2002230997A1 (en) * 2000-12-15 2002-06-24 Genetics Institute, Llc Methods and compositions for diagnosing and treating rheumatoid arthritis
WO2002085285A2 (en) * 2001-04-18 2002-10-31 Wyeth Methods and reagents for regulating bone and cartilage formation
US20030138792A1 (en) * 2001-05-31 2003-07-24 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer
AU2002318944A1 (en) * 2001-08-01 2003-02-17 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
US20030148334A1 (en) * 2001-10-12 2003-08-07 Zairen Sun Differentially-expressed genes and polypeptides in angiogenesis
EP1527196A4 (en) * 2002-03-01 2007-03-14 Childrens Hosp Medical Center TREATMENT OF ASTHMA AND ALLERGIES
US20040018522A1 (en) * 2002-05-09 2004-01-29 Brigham And Women's Hospital, Inc. Identification of dysregulated genes in patients with multiple sclerosis
US20050003390A1 (en) * 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
JP2004041121A (ja) * 2002-07-12 2004-02-12 Hitachi Ltd アレルギー解析方法及びシステム
US7482117B2 (en) * 2002-12-20 2009-01-27 Celera Corporation Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
EP1613269B1 (en) * 2003-04-04 2015-02-25 Incyte Corporation Compositions, methods and kits relating to her-2 cleavage
US20050009067A1 (en) * 2003-05-19 2005-01-13 Craig Logsdon Expression profile of pancreatic cancer
US20050059101A1 (en) * 2003-09-10 2005-03-17 Gordon Ringold Bivalent targeting of cell surfaces

Also Published As

Publication number Publication date
WO2001009189A3 (en) 2001-06-14
JP2003508028A (ja) 2003-03-04
DE60045247D1 (de) 2010-12-30
ATE488529T1 (de) 2010-12-15
US7226596B2 (en) 2007-06-05
AU776600B2 (en) 2004-09-16
ES2355055T3 (es) 2011-03-22
US20080175842A1 (en) 2008-07-24
WO2001009189A2 (en) 2001-02-08
US20030113764A1 (en) 2003-06-19
EP1204682B1 (en) 2010-11-17
EP1204682A2 (en) 2002-05-15
JP2012068254A (ja) 2012-04-05
JP5897300B2 (ja) 2016-03-30
CA2378182A1 (en) 2001-02-08
JP2014144959A (ja) 2014-08-14
AU6391300A (en) 2001-02-19

Similar Documents

Publication Publication Date Title
AU2003200740B2 (en) Compositions and methods for the treatment of tumor
US20080175842A1 (en) Compositions and methods for treatment
WO2000053755A2 (en) Compositions and methods for the treatment of tumor
US20070141068A1 (en) Methods for the treatment of carcinoma
US20050176104A1 (en) Compositions and methods for the treatment of tumor
EP1657256A2 (en) Compositions and methods for the treatment of tumor
AU2006241374B2 (en) Novel Stra6 polypeptides
AU2004201769B2 (en) Compositions and methods for the treatment of tumors
WO2000037640A9 (en) Compositions and methods for the treatment of tumor
WO2000015666A2 (en) Compositions and methods for the treatment of tumors
WO2001005836A1 (en) Polypeptidic compositions and methods for the treatment of tumors
EP1145011B1 (en) Compositions and methods for the diagnosis and treatment of tumor
US20020146707A1 (en) Cardiotrophin-1 compositions and methods for the treatment of tumor
AU756400B2 (en) Compositions and methods for the treatment of tumor
AU2003200721C1 (en) Compositions and methods for the treatment of tumor
US7258983B2 (en) Cardiotrophin-1 compositions and methods for the treatment of tumor

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20200727